

## Response to: 'Correspondence on: 'Warfarin use and risk of knee and hip replacements'' by He *et al*

We thank the authors for their interest in our work.<sup>1-3</sup> Their approach and results provide yet additional support to the adverse impact of warfarin on osteoarthritis outcomes, as compared with direct oral anticoagulants.

Priyanka Ballal,<sup>1</sup> Christine Peloquin,<sup>2</sup> Cindy Germaine Boer ,<sup>3</sup> Tuhina Neogi <sup>4</sup>

<sup>1</sup>Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA

<sup>2</sup>Clinical Epidemiology Unit, Boston University, Boston, Massachusetts, USA

<sup>3</sup>Internal Medicine, Genetic Laboratories, Erasmus MC, Rotterdam, Netherlands

<sup>4</sup>Section of Rheumatology, Boston University, Boston, Massachusetts, USA

**Correspondence to** Dr Tuhina Neogi, Section of Rheumatology, Boston University, Boston, MA 2118, USA; tneogi@bu.edu

**Twitter** Cindy Germaine Boer @CurlyGeneticist

**Contributors** PB was involved in drafting the response and critical revision. CP and TN were involved in critical revision.

**Funding** This work and CP were supported by NIH P30AR072571. TN was supported by NIH K24AR070892. Sponsors played no role in the conduct of the study or preparation of this manuscript.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Ethics approval** Boston University Medical Campus Institutional Review Board (protocol H-32821).

**Provenance and peer review** Commissioned; internally peer reviewed.

**Data availability statement** Deidentified data were used for this work. These data are not publicly available. The IMRD dataset used in this work is a subscription-based dataset with a legal contract requiring data to remain onsite and analysed at Boston University Medical Center. We are therefore legally unable to make these data publicly available. We would be able to collaborate with potential external investigators to address research questions of interest if appropriate resources are provided. Investigators may contact IMRD for further information about obtaining data.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.



**To cite** Ballal P, Peloquin C, Boer CG, *et al*. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2021-220855

Received 25 May 2021

Accepted 27 May 2021



► <http://dx.doi.org/10.1136/annrheumdis-2021-220819>

*Ann Rheum Dis* 2021;0:1. doi:10.1136/annrheumdis-2021-220855

### ORCID iDs

Cindy Germaine Boer <http://orcid.org/0000-0003-4809-0044>

Tuhina Neogi <http://orcid.org/0000-0002-9515-1711>

### REFERENCES

- 1 He N, Fang Z, Li X. Correspondence on: "Warfarin use and risk of knee and hip replacements". *Annals of the Rheumatic Diseases* 2021.
- 2 Ballal P, Peloquin C, Boer CG, *et al*. Warfarin use and risk of knee and hip replacements. *Ann Rheum Dis* 2021;80:605–9.
- 3 Boer CG, Szilagyi I, Nguyen NL, *et al*. Vitamin K antagonist anticoagulant usage is associated with increased incidence and progression of osteoarthritis. *Ann Rheum Dis* 2021;80:598–604.